Hopp til innhold

Vaccination for Human Papillomavirus (HPV) (Indicator 22)

Published Updated

The indicator describes the following: Availability and coverage of human papilloma virus (HPV) vaccine.

The indicator describes the following: Availability and coverage of human papilloma virus (HPV) vaccine.


A vaccine against human papillomavirus (HPV) has been part of the Norwegian Childhood Immunisation Programme since 2009 and is given at the age of 12. The vaccine has been offered to girls since 2009 and to boys since 2018. The Norwegian Immunisation Registry (SYSVAK) provides vaccination coverage statistics for HPV vaccination. 

Results

HPV vaccination coverage among 16-year-old girls increased from 67 per cent to 88 per cent between 2013 and 2018. The vaccination coverage for fully-vaccinated boys will not be available until 2023, but the proportion of boys who have had at least one dose of HPV vaccine is 87 per cent. 59 per cent of young women born between 1991 and 1996 have had at least one dose of HPV vaccine during the time-limited vaccination programme. This is shown by data from the Norwegian Immunisation Registry (SYSVAK).

Figure 1
Figure 1: HPV vaccination coverage among girls aged 16 years, as a percentage. Source: Norwegian Immunisation Registry SYSVAK. See table below.

Table accompanying Figure 1

Table 1HPV vaccination coverage among girls aged 16, as a percentage. Source: Norwegian Immunisation Registry SYSVAK. 

2013

2014

2015

2016

2017

2018

67.1

76.3

78.7

81.1

88.1

88.3

 

Data source: Norwegian Immunisation Registry (SYSVAK)

The data source for this indicator is the Norwegian Immunisation Registry (SYSVAK). A description follows below.

Description 

The Norwegian Immunisation Registry (SYSVAK) maintains an overview of the individual's vaccination status and vaccination coverage in Norway. 

The Norwegian Childhood Immunisation Programme includes a range of different vaccines recommended by the health authorities for children and adolescents. Basic vaccination is mainly given to infants and young children, and booster doses for many of the vaccines are offered to school-age children.

The Norwegian Institute of Public Health is responsible for procuring the vaccines for the Norwegian Childhood Immunisation Programme and distributing them to the municipalities. Vaccination takes place at public health clinics and through the school health service and is free of charge. All administered vaccines are registered at individual level in SYSVAK.

The Norwegian Childhood Immunisation Programme publishes an annual report that includes coverage statistics, reported cases of diseases for which vaccination is provided, the type of vaccines that have been used.

Effect measure

  • Vaccination coverage for girls aged 16 years who are fully vaccinated with the  HPV vaccine, as a percentage. 

The figures apply to those who are fully vaccinated, i.e. they have received the recommended three doses at the recommended time. The vaccine against human papilloma virus (HPV) had been administered in three doses since 2009. Since 2017, the vaccine has been administered in two doses as part of the Childhood Immunisation Programme (begun before turning 15 years).

The vaccine is offered at the age of 12.  Vaccination coverage is calculated at the age of 16. Boys have been offered the vaccine as part of the Childhood Immunisation Programme since the 2018/2019 school year and these vaccination coverage statistics  will be published in 2023. From November 1st 2016 til June 20th 2019, a temporary follow-up programme allowed young women born in 1991 or later who were never offered/had declined the vaccine as part of the Childhood Immunisation Programme to be vaccinated. 

Global indicator definition

WHO’s definition of the indicator

Indicator 22. Availability, as appropriate, if cost-effective and affordable, of vaccines against human papillomavirus, according to national programmes and policies. 

About this page